Keros Therapeutics (Keros Therapeutics) Interest Coverage : N/A (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Keros Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Keros Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-44.06 Mil. Keros Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Keros Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Keros Therapeutics's Interest Coverage or its related term are showing as below:

KROS's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 137.02
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Keros Therapeutics Interest Coverage Historical Data

The historical data trend for Keros Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Keros Therapeutics Interest Coverage Chart

Keros Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

N/A

Keros Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Keros Therapeutics's Interest Coverage

For the Biotechnology subindustry, Keros Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's Interest Coverage falls into.

Keros Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Keros Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Keros Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-167.54 Mil. And its Long-Term Debt & Capital Lease Obligation was $13.44 Mil.

GuruFocus does not calculate Keros Therapeutics's interest coverage with the available data.

Keros Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Keros Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-44.06 Mil. And its Long-Term Debt & Capital Lease Obligation was $13.44 Mil.

GuruFocus does not calculate Keros Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

Keros Therapeutics (NAS:KROS) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Keros Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Keros Therapeutics (Keros Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421

Website

https://www.kerostx.com

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Executives

Keith Regnante	officer: Chief Financial Officer	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Jennifer Lachey	officer: Chief Scientific Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Christopher Rovaldi	officer: Chief Operating Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Julius Knowles	director	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Simon Peter Cooper	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Claudia Ordonez	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Tomer Kariv	director, 10 percent owner	C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Ran Nussbaum	director, 10 percent owner	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jasbir Seehra	director, officer: Chief Executive Officer	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Arkin Bio Ventures Limited Partnership	10 percent owner	6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406